U.S.-based medical device company Micro Interventional Devices Inc. (MID), has raised about $20 million in Series D round of financing.
With the support, MID will complete its ongoing study of transcatheter tricuspid annular repair clinical trial.
The round was headed by U.S. medical device solutions company Oscor, with contributions from Originate Ventures, LifeSciences Greenhouse, Ben Franklin Venture Partners, and other existing shareholders.
As part of the round, Oscor will join Micro Interventional Devices’ board of directors.